|
Biological Deviation Reports May Spur ‘Direct’ Recall: CBER Officials
TAMPA, Fla. — Now that CBER’s all-electronic Direct Recall Classification (DRC) program has been extended to non-blood products, problems with biologic drugs flagged in electronic biological product deviation reports (eBPDRs) may trigger recalls of those products under the program.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives